Dialysis Modality, Vascular Access and Mortality in End-stage Kidney Disease: A Bi-national Registry-based Cohort Study
Overview
Affiliations
Aim: There remains debate on which dialysis modality offers better survival outcomes for patients. We compare the survival of patients undergoing home haemodialysis (HD) with a permanent vascular access, facility HD with a permanent vascular access, facility HD with a central venous catheter or peritoneal dialysis.
Methods: We considered adult patients from the Australia and New Zealand Dialysis and Transplant Registry who commenced dialysis between 1 October 2003 and 31 December 2011. Patients were followed until death, transplant, loss to follow-up or 31 December 2011. Marginal structural models for mortality were used to account for time-varying treatment, comorbidities and baseline covariates. Unmeasured differences between treatment groups may remain even after adjustment for measured differences, so the potential effects of unmeasured confounding were explicitly modelled.
Results: There were 20,191 patients who underwent ≥90 days of dialysis (median 2.25 years, interquartile range 1-3.75 years). There were significant differences in age, gender, comorbidities and other variables between treatment groups at baseline. Thirty per cent of patients had at least one treatment change. Relative to facility HD with permanent access, the risk of death for home HD patients with a permanent access was lower in the first year (at 9 months: hazard ratio 0.41, 95% CI 0.25-0.67, adjusted for all baseline covariates). Findings were robust to unmeasured confounding within plausible ranges.
Conclusion: Relative to facility HD with permanent vascular access, home HD conferred better survival prospects, while peritoneal dialysis was associated with a higher risk and facility HD with a catheter the highest risk, especially within the first year of dialysis.
Patient Perspectives on Arteriovenous Fistula Placement, Maturation, and Use: A Qualitative Study.
Patel D, Churilla B, Lee T, Thamer M, Zhang Y, Allon M Kidney Med. 2024; 6(12):100919.
PMID: 39634335 PMC: 11615592. DOI: 10.1016/j.xkme.2024.100919.
Streamlining Preoperative Evaluation for Dialysis Access: A Pilot Study.
Radomski S, Sorber R, Ruck J, Haugen C, Holscher C, Ganti A Ann Vasc Surg. 2024; 110(Pt A):153-159.
PMID: 39369887 PMC: 11634663. DOI: 10.1016/j.avsg.2024.08.002.
Home versus in-centre haemodialysis for people with kidney failure.
Cheetham M, Ethier I, Krishnasamy R, Cho Y, Palmer S, Johnson D Cochrane Database Syst Rev. 2024; 4:CD009535.
PMID: 38588450 PMC: 11001293. DOI: 10.1002/14651858.CD009535.pub3.
Harduin L, Barroso T, Guerra J, Filippo M, de Almeida L, de Castro-Santos G J Vasc Bras. 2023; 22:e20230052.
PMID: 38021275 PMC: 10648056. DOI: 10.1590/1677-5449.202300522.
Forcey D, Tran D, Connor J, Ayudhya P, Ocampo C, Nelson C BMC Nephrol. 2023; 24(1):268.
PMID: 37704969 PMC: 10500889. DOI: 10.1186/s12882-023-03321-z.